Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World).

Semaglutide 2.4 mgno clear effectLower rMACE-5, no range given.No ranges given.

What the trial testedas reported · 18,642 people · 2025

No range given

−45%

semaglutide 2.4 mg vs not on semaglutide

Bigger than 9 in 10 for cardiovascular events

As reported

HR 0.55, no interval

45,456people in the Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World trial, from 2024

18,642of them with cardiovascular disease, aged 45+, in this paper

The trial randomly assignedassigned by chance

semaglutide 2.4 mg

not on semaglutide

Reported lower rMACE-5, no range given−45%

randomised

the abstract, start to end

… lower risks of rMACE-5 (hazard ratio: 0.55; p < 0.001), rMACE-3 (0.43; …

← favours treatmentfavours comparator →

could be chance

No interval given · direction only, strength unknown

RMACE-5semaglutide 2.4 mg vs not on semaglutide

HR 0.55

GLP-1 receptor agonistsCardiovascular events

1 / 4

2025

2026

this papercites it